1. Detection of the SARS-CoV-2 humanized antibody with paper-based ELISA
- Author
-
Muhammad Umer, Surasak Kasetsirikul, Nam-Trung Nguyen, Kamalalayam Rajan Sreejith, Muhammad J. A. Shiddiky, and Narshone Soda
- Subjects
Paper ,Enzyme-Linked Immunosorbent Assay ,02 engineering and technology ,Antibodies, Monoclonal, Humanized ,Antibodies, Viral ,010402 general chemistry ,medicine.disease_cause ,Humanized antibody ,Proof of Concept Study ,01 natural sciences ,Biochemistry ,Horseradish peroxidase ,Armoracia ,Analytical Chemistry ,law.invention ,COVID-19 Testing ,Antigen ,Limit of Detection ,law ,Electrochemistry ,medicine ,Coronavirus Nucleocapsid Proteins ,Humans ,Environmental Chemistry ,Horseradish Peroxidase ,Spectroscopy ,Coronavirus ,Detection limit ,Chromatography ,biology ,SARS-CoV-2 ,Chemistry ,Benzidines ,COVID-19 ,Repeatability ,Phosphoproteins ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,3. Good health ,Recombinant DNA ,biology.protein ,Colorimetry ,Antibody ,0210 nano-technology - Abstract
This work reports the development of a rapid, simple and inexpensive colorimetric paper-based assay for the detection of the severe acute respiratory symptom coronavirus 2 (SARS-CoV-2) humanized antibody. The paper device was prepared with lamination for easy sample handling and coated with the recombinant SARS-CoV-2 nucleocapsid antigen. This assay employed a colorimetric reaction, which is followed by horseradish peroxidase (HRP) conjugated detecting antibody in the presence of the 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The colorimetric readout was evaluated and quantified for specificity and sensitivity. The characterization of this assay includes determining the linear regression curve, the limit of detection (LOD), the repeatability, and testing complex biological samples. We found that the LOD of the assay was 9.00 ng μL-1 (0.112 IU mL-1). The relative standard deviation was approximately 10% for a sample number of n = 3. We believe that our proof-of-concept assay has the potential to be developed for clinical screening of the SARS-CoV-2 humanized antibody as a tool to confirm infected active cases or to confirm SARS-CoV-2 immune cases during the process of vaccine development.
- Published
- 2020
- Full Text
- View/download PDF